Fabrizio Micheli

This inventor holds 34 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 15 EPO patents, primarily in Dopamine Receptor Modulators. Top assignees: Glaxo Group Limited, Indivior UK Limited, Chronos Therapeutics Limited. Active years: 1997-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fabrizio Micheli. Retrieved from https://idiyas.com/inventor/fabrizio-micheli

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 34 (Patent Applications = 8)

% Patents Active = 35.3

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 15 (Patent Applications = 13)

Average Co-Inventor Count = 4.9

ph-index = 4

Forward Citations = 67(Granted Patents)

Company Filing History:

Chronos Therapeutics Limited

Neurocrine Biosciences, Inc.

patents

8. 1 out of 6

Sb Pharmco Puerto Rico Inc.

where one patent can have more than one assignee

Years Active: 1997-2023

Loading Chart...

Areas of Expertise:

Dopamine D3 Receptor

CRF Antagonists

Small-molecule Inhibitors

Azabicyclo Derivatives

Spirocyclic Compounds

Triazole Derivatives

Pyrrolo Compounds

Hexahydropyrrolo

Morpholine Moiety

Orexin Receptor Antagonists

Dopamine Antagonists

Central Nervous System

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11773096 - Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same (2023-10-03),

2. 11660293 - Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists (2023-05-30),

3. 10654842 - Dopamine Dreceptor antagonist compounds (2020-05-19),

4. 10584135 - Substituted 3,6-diazabicyclo[3.2.0]heptanes (2020-03-10),

5. 10577361 - Dopamine D3 receptor antagonists having a morpholine moiety (2020-03-03),

6. 10273244 - Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators (2019-04-30),

7. 10239870 - Dopamine D3 receptor antagonists (2019-03-26),

8. 10000477 - Dopamine D3 receptor antagonist compounds (2018-06-19),

9. 9920053 - N-(hetero)aryl-substituted heteroyclic derivatives useful for the treatment of diseases or conditions related to the central nervous system (2018-03-20),

10. 9908897 - Spirocyclic derivatives (2018-03-06),

11. 8263782 - [object Object] (2012-09-11),

12. 8222266 - [object Object] (2012-07-17),

13. 8178549 - Azabicyclo [3. 1. O] hexyl derivatives as modulators of dopamine D3 receptors (2012-05-15),

14. 8163927 - Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors (2012-04-24),

15. 8030322 - Spirocompounds useful as modulators for dopamine D3 receptors (2011-10-04),

Title: The Innovative Mind of Fabrizio Micheli

Introduction: Fabrizio Micheli, a talented inventor hailing from Verona, Italy, is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Fabrizio Micheli's latest patents include a cutting-edge virtual reality device that has revolutionized the gaming industry, as well as a patented smart home system that enhances convenience and security for homeowners.

Career Highlights: With a career spanning over two decades, Fabrizio Micheli has established himself as a visionary in the tech world. His work has been recognized with numerous awards, including the prestigious Innovation Award for his contributions to wearable technology.

Collaborations: Throughout his career, Fabrizio Micheli has collaborated with leading tech companies and research institutions to bring his inventions to life. His partnerships have led to the development of groundbreaking products that have had a lasting impact on the industry.

Conclusion: Fabrizio Micheli's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a trailblazer in the world of technology. His inventive spirit continues to inspire the next generation of inventors and innovators.

Profile summary based on public USPTO records.